DiMe’s sDHT Adoption Navigator helps clinical teams move from guidance to action, but the real test is whether organizations use it early enough to matter.
- Why Clinical Trial Data Cleaning Must Go Continuous (And How To Do It)
- What Clinical Analytics Solutions Are Shaping Clinical Research
- Sites Are Building Their Own Tech – SCRS On What That Means
- Human-In-The-Loop In AI Validation And Control: From Principle To Practice
- When The System Breaks, Who Pays? SCRS On Site Tech Gaps
- HTA, Digital Twins, And Building Clinical Tech That Lasts
- Real-World Evidence And Wearables Are Reshaping Trial Tech
- Navigating Elsa's AI Transition: Practical Guidance To Safeguard Confidential Information (Part 3)
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
To Counter Bias, Counterbalance
It’s easy to overlook the effects a survey’s format can have on responses, but those effects are potent sources of bias. Modern EDC allows you to systematically vary both question and response option order. This practice, called counterbalancing, guards against unwanted order effects.
-
Guide: Switching To A New EDC System
Read to learn five key tips when switching to a new EDC system, including best practices for change management, process and people training, KPIs, and more.
-
Growing Pains: The Real Story Behind Gen AI Development In Clinical Trial Ops
As Gen AI develops and reaches advanced stages it introduces risks such as model hallucinations, which can affect trial accuracy and reliability. Explore how to address these challenges.
-
Overcoming 5 Challenges Of Implementing eClinical Technologies
Assess five common pitfalls trial teams face when incorporating new technology and identify potential solutions to mitigate the common risks.
-
Building A Gold Standard Trial Experience In Japan
Hear how Medable worked with a Japanese sponsor to elevate their trial experience, achieve >90% patient and site adherence, and beat their forecasted FPI date, creating new eCOA standards adopted across all the customer’s vendors.
-
RBQM For Decentralized Trials: Two Key Areas Of Focus To Reduce Your Risk
This article takes a more in-depth look at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ in ICH-GCP E6 R2 to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.
-
Kicking Off A Clinical Trial The Right Way - With Seamless Digital Consent
Read this blog to learn more about how eConsent can enhance participant engagement and retention when used both onsite and remotely.
-
Defining 'Evidence Generation' Within Modern Clinical Trials
Learn how this distinctive approach centered on enabling clinical trial sponsors to gather data and generate evidence ensures the successful acquisition of diverse information.
-
The Strategic Role Of KOLs In Rare Disease Drug Development
Engaging key Opinion Leaders (KOL) is crucial for accelerating rare disease research breakthroughs. However, identifying the right experts is challenging due to fragmented data and evolving expertise.
-
Partnership Driving Superior Enrollment And Speed In Phase III Trial
Examine the partnership between CRIO and Sitero, including how it underscores the significant impact of technology in optimizing trial performance and accelerating treatment development.
- DiMe's Navigator: Why Teams Still Stall On Digital Endpoints
- Digital Endpoints Are Ready. Clinical Development Isn't
- Why Clinical Trial Data Cleaning Must Go Continuous (And How To Do It)
- Sites Are Building Their Own Tech – SCRS On What That Means
- When The System Breaks, Who Pays? SCRS On Site Tech Gaps
RECENT NEWSLETTERS
- 05.07.26 -- How AI, ICH E6(R3) & RWD Are Reshaping Clinical Trials
- 05.02.26 -- Best Of April: AI In Clinical Trials — What Working
- 04.30.26 -- AI, RWE & Predictive Analytics Are Reshaping Trials
- 04.23.26 -- Smarter Trials Start Here: Data Quality, AI & Infrastructure Insights
- 04.16.26 -- 5 eTMF Questions, Agentic AI's Real Impact On Clinical Trials & More